Metals, membranes, and amyloid-β oligomers: Key pieces in the Alzheimer's disease puzzle?

Journal of Alzheimer's Disease

Volumn 33, Issue SUPPL. 1, 2013, Pages

  Watt, Andrew D ^a,b   Villemagne, Victor L ^a,c   Barnham, Kevin J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

Biomarker; blood; copper; mass spectrometry; metal chaperone; NMDA; toxicity; zinc

Indexed keywords

AMPA RECEPTOR; AMYLOID BETA PROTEIN; CLIOQUINOL; COPPER; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TAU PROTEIN; TRANSITION ELEMENT; ZINC;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; BETA SHEET; BINDING SITE; BLOOD BRAIN BARRIER; CALCIUM TRANSPORT; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DRUG SAFETY; DRUG TOLERABILITY; ELECTRON SPIN RESONANCE; GAIN OF FUNCTION MUTATION; HUMAN; HYDROPHOBICITY; LIPID MEMBRANE; LUMBAR PUNCTURE; METAL BINDING; NERVE ENDING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84872539362     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-129017     Document Type: Review

References (72)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403
2. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ (2010) Blood borne amyloidbeta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 30, 6315-6322
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
4. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17, 1060-1065
5. Sperling RA, Jack CR, Aisen PS (2011)Testing the right target and right drug at the right stage. Sci Transl Med 3, 111 cm 133
6. Cappai R, Barnham K (2008) Delineating the mechanism of Alzheimer's diseaseAbeta peptide neurotoxicity. Neurochem Res 33, 526-532
7. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862
8. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866
9. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214
10. Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ (2009) Pleomorphic copper coordination by Alzheimer's disease amyloid- peptide. J Am Chem Soc 131, 1195-1207
11. Faller P, Hureau C (2009) Bioinorganic chemistry of copper and zinc ions coordinated to amyloid- peptide. Dalton Trans, 1080-1094
12. Drew SC, Masters CL, Barnham KJ (2009) Alanine-2 Carbonyl is an Oxygen Ligand in Cu2+ Coordination of Alzheimer's Disease Amyloid- Peptide - Relevance to NTerminallyTruncated Forms. JAmChemSoc 131, 8760-8761
13. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL, Tew DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL, Cappai R, Barnham KJ (2006) Copper-Mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281, 15145-15154
14. Barnham KJ, Bush AI (2008) Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 12, 222-228
15. Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ (2005) Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-Like structures and inhibition of neurotoxicity. J Biol Chem 280, 13355-13363
16. Smith DG, Ciccotosto GD, Tew DJ, Perez K, Curtain CC, Boas JF, Masters CL, Cappai R, Barnham KJ (2010) Histidine 14 modulates membrane binding and neurotoxicity of the Alzheimer's disease amyloid-beta peptide. J Alzheimers Dis 19, 1387-1400
17. Ciccotosto GD, Tew DJ, Drew SC, Smith DG, Johanssen T, Lal V, Lau T-L, Perez K, Curtain CC, Wade JD, Separovic F, Masters CL, Smith JP, Barnham KJ, Cappai R (2011) Stereospecific interactions are necessary for Alzheimer disease amyloid- Toxicity. Neurobiol Aging 32, 235-248
18. Butterfield DA, Bush AI (2004) Alzheimer's amyloid -Peptide (1-42): Involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25, 563-568
19. Butterfield DA (1997) -Amyloid-Associated free radical oxidative stress and neurotoxicity - implications for Alzheimer's disease. Chem Res Toxicol 10, 495-506
20. Butterfield DA, Boyd-Kimball D (2004) Amyloid betapeptide
21. 1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 14, 426-432
22. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J (1994) -Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-Specific fashion: Implications to Alzheimer's disease. Biochem Biophys Res Commun 200, 710-715
23. Bush AI, Huang XD, Fairlie DP (1999) The possible origin of free radicals from amyloid b peptides in Alzheimer's disease. Neurobiol Aging 20, 335-337
24. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R (2003) Neurotoxic, redox-competent Alzheimer's -Amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278, 42959-42965
25. Lau T-L, Ambroggio EE, Tew DJ, Cappai R, Masters CL, Fidelio GD, Barnham KJ, Separovic F (2006) Amyloid-peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol 356, 759-770
26. Russ WP, Engelman DM (2000) The GxxxG motif: A framework for transmembrane helix-helix association. J Mol Biol 296, 911-919
27. LiuW, Crocker E, ZhangW, Elliott JI, Luy B, Li H, Aimoto S, Smith SO (2005) Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices. Biochemistry 44, 3591-3597
28. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ (2008) Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci 28, 11950-11958
29. Lee G, Pollard HB, Arispe N (2002) Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-Peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23, 1249-1263
30. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791
31. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI (2010) Cognitive loss in zinc transporter-3 knock-out mice: A phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci 30, 1631-1636
32. Schlief ML, Gitlin JD (2006) Copper homeostasis in the CNS: A novel link between the NMDA receptor and copper homeostasis in the hippocampus. Mol Neurobiol 33, 81-90
33. Schlief ML, West T, Craig AM, Holtzman DM, Gitlin JD (2006) Role of the Menkes copper-Transporting ATPase in NMDA receptor-Mediated neuronal toxicity. Proc Natl Acad Sci U S A 103, 14919-14924
34. Ridge PG, Zhang Y, Gladyshev VN (2008) Comparative genomic analyses of copper transporters and cuproproteomes reveal evolutionary dynamics of copper utilization and its link to oxygen. PLoS One 3, e1378
35. Franz KJ (2008) Copper shares a piece of the pi. Nat Chem Biol 4, 85-86
36. Schlief ML, CraigAM,Gitlin JD (2005)NMDAreceptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 25, 239-246
37. Terry RD (1996) The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55, 1023-1025
38. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52
39. Smart TG, Hosie AM, Miller PS (2004) Zn2+ ions: Modulators of excitatory and inhibitory synaptic activity. Neuroscientist 10, 432-442
40. Gleichmann M, Mattson MP (2011) Neuronal calcium homeostasis and dysregulation. Antiox Redox Signal 14, 1261-1273
41. Ferrada E, Arancibia V, Loeb B, Norambuena E, Olea-Azar C, Huidobro-Toro JP (2007) Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy. Neurotoxicology 28, 445-449
42. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-Amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676
43. RitchieCW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metalprotein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691
44. Barnham KJ, Gautier E, Kok G, Krippner G (2003) 8-hydroxyquinoline derivatives. PCT Publication WO2004007461
45. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55
46. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786
47. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J Alzheimers Dis 20, 509-516
48. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-Peptide by metal-Dependent up-regulation of metalloprotease activity. J Biol Chem 281, 17670-17680
49. Caragounis A, Du T, Filiz G, Laughton KM, Volitakis I, Sharples RA, Cherny RA, Masters CL, Drew SC, Hill AF, Li QX, Crouch PJ, Barnham KJ, White AR (2007) Differential modulation of Alzheimer's disease amyloid beta-Peptide accumulation by diverse classes of metal ligands. Biochem J 407, 435-450
50. Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ, Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL, Bush AI, Barnham KJ, White AR (2011) The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation andGSK3phosphorylation via ametal chaperone activity. J Neurochem 119, 220-230
51. Beraldo H, Gambino D (2004) The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. Mini Rev Med Chem 4, 31-39
52. Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, Welch M (2001) Copper-64-Diacetyl-bis(N4-Methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci U S A 98, 1206-1211
53. Green MA, Klippenstein DL, Tennison JR (1988) Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J Nucl Med 29, 1549-1557
54. Kraker A, Krezoski S, Schneider J, Minkel D, Petering DH (1985) Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) Cu(II) with Ehrlich cells. Binding of copper to metallothionein and its relationship to zinc metabolism and cell proliferation. J Biol Chem 260, 13710-13718
55. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, McCarthy T, McCarthy DW, Gambhir SS (2002) Ex vivo cell labeling with 64Cu-Pyruvaldehyde-bis (N4-Methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A 99, 3030-3035
56. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, YokoyamaA(1997) Copper-62-ATSM:Anewhypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38, 1155-1160
57. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ (2002) Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure-Activity relationships. J Biol Inorg Chem 7, 249-259
58. Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li QX, Masters CL, Barnham KJ, White AR (2008) Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 283, 4568-4577
59. Fodero-Tavoletti MT, Villemagne VL, Paterson BM, White AR, Li QX, Camakaris J, O'Keefe G, Cappai R, Barnham KJ, Donnelly PS (2010) Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. J Alzheimers Dis 20, 49-55
60. Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li QX, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR, Barnham KJ (2009) Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 106, 381-386
61. Humpel C (2011) Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 29, 26-32
62. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144
63. Marksteiner J, Hinterhuber H, Humpel C (2007) Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-Amyloid(1-42), tau, phospho-Tau-181 and total protein. Drugs Today 43, 423-431
64. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D (2005) Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19, 220-225
65. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79, 1331-1338
66. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL (2007) In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27, 10365-10371
67. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) beta-Amyloid imaging and memory in non-Demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844
68. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL,Kung HP, ZhangW,KungMP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL (2008) Imaging of amyloid in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7, 129-135
69. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE,Mathis CA, Price JC, Masters CL,Villemagne VL (2007) Imaging beta-Amyloid burden in aging and dementia. Neurology 68, 1718-1725
70. Villemagne VL, Perez KA, Pike KE, Rowe CC, Masters CL, White AR, Bedo J, Faux NG, Barnham KJ (2010) Blood borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 30, 6315-6322
71. Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ (2010) Increasing the predictive accuracy of amyloid-beta blood-borne biomarkers in Alzheimer's disease. J Alzheimers Dis 24, 47-59
72. Alzheimer's Association (2010) 2010 Alzheimer's disease facts and figures. Alzheimers Dement 6, 158-194